ERBB2 and congestive heart failure: Cardiotoxic effects most frequently experienced by patients treated with anti-HER2 therapies include asymptomatic drops in left ventricular ejection fraction (LVEF), and left ventricular systolic dysfunction (LVSD), or congestive heart failure (CHF) (Gonciar et al., 2021; Pondé et al., 2016; Florido et al., 2017).